On Machine Learning in Medicine and More

TL;DR

Andreessen Horowitz general partner, Vijay Pandey, discusses the potential of software and machine learning to revolutionize the healthcare industry by de-risking investments, scaling behavioral therapies, and creating novel approaches to diagnostics and therapeutics.

Transcript

so I'm delighted to be joined today by Vijay Pandey a general partner at Andreessen Horowitz Vijay joined the firm at full time as a general partner last year to manage the new bio phones that andreessen horowitz raised so I'm interested Vijay what's a what's a biotech guy like you if it had a long and distinguished career in on the academic side d... Read More

Key Insights

• 🙃 Software and machine learning have the potential to de-risk investments and drive revenue growth in the healthcare sector.
• ⚖️ Digital therapeutics aim to scale existing behavioral therapies for improved accessibility and outcomes.
• 💊 Computational medicine utilizes machine learning for early detection and personalized medicine.
• 👨‍🔬 Cloud biology seeks to make biology resemble programming, enabling novel approaches to research and therapeutics.
• 🚨 Entrepreneurs with expertise in both technology and life sciences are emerging, driving innovation in the sector.
• 💦 Working within the existing regulatory framework can be an opportunity for companies to shape industry practices and establish barriers to entry.
• 🛟 Traditional life science companies and technology giants may be potential acquirers of innovative healthcare startups.

Questions & Answers

Q: How does software differ from traditional biotech in terms of risk and investment?

Software allows for de-risking at every stage of investment, leading to greater revenue growth. Unlike biotech, software investments don't require large amounts of money upfront and have more predictable outcomes.

Q: What are the main areas of focus for Andreessen Horowitz in the healthcare sector?

Andreessen Horowitz focuses on digital therapeutics, computational medicine, and cloud biology. These areas encompass scaling behavioral therapies, leveraging machine learning for diagnostics, and making biology resemble programming.

Q: Why is now the right time for software-driven healthcare innovation?

The combination of machine learning, mobile technology, and existing therapies can revolutionize healthcare delivery. Mobile technology allows for more widespread access to behavioral therapies, while machine learning enables accurate diagnostics at an early stage.

Q: What challenges do entrepreneurs face in disrupting the healthcare industry?

Working within the existing regulatory framework is a challenge, but it also presents an opportunity for companies to shape best practices. Collaboration with regulators can lead to establishing barriers to entry and potential partnerships with incumbents.

Summary

In this video, Vijay Pandey, a general partner at Andreessen Horowitz, discusses the role of technology in the field of biotech and the potential impact it can have on healthcare. He highlights the areas of focus for venture funding, such as digital therapeutics, computational medicine, and cloud biology. He also talks about the challenges and opportunities in this space, including working with regulatory agencies and the potential for mergers and acquisitions. Pandey shares his insights on the potential future of healthcare and the importance of multidisciplinary entrepreneurs in driving innovation.

Questions & Answers

Q: What is the role of bio in the tech space and how is it different from biotech?

The role of bio in the tech space is distinct from traditional biotech. While biotech carries a lot of risk and requires significant investment, software can be de-risked at every stage and has the potential for greater revenue. The opportunity is to apply the software approach to biology and leverage technologies like machine learning and cloud computing to make an impact in the field.

Q: What are the specific areas of focus for venture funding in this space?

The specific areas of focus are digital therapeutics, computational medicine, and cloud biology. Digital therapeutics involve scaling existing behavioral therapies for conditions like type 2 diabetes and anxiety through technology. Computational medicine applies machine learning to medical data, enabling early detection and improved diagnosis. Cloud biology is an emerging field where companies are leveraging the ability to program biology and make it more efficient and scalable.

Q: Why is now the right time for this approach in healthcare technology?

The combination of machine learning and mobile technology has opened up new possibilities in healthcare. Mobile platforms allow for widespread adoption of behavioral therapies, while machine learning algorithms can analyze large amounts of medical data for improved diagnostics. These advancements create a unique opportunity to transform the way healthcare is delivered.

Q: How do you see this approach impacting the future of healthcare?

This approach has the potential to revolutionize healthcare by making behavioral therapies more scalable, enabling early detection of diseases through computational medicine, and making biology more programmable. By combining data science and mobile technology with existing therapies and technologies, healthcare can be delivered more effectively and on a larger scale.

Q: Where are the entrepreneurs in this space coming from?

There is a new breed of entrepreneur emerging, one who has expertise in both technology and life sciences. These individuals understand both the computer science and biology aspects of the field, which allows for unique insights and the ability to bridge the gap between the two disciplines. This multidisciplinary approach is critical in driving innovation in this space.

Q: How do you navigate the challenges presented by the existing healthcare industry?

While there are challenges working within the existing healthcare system, there are also opportunities for collaboration and innovation. By working with regulators and demonstrating the value of new technologies and therapies, companies can help shape the industry and build barriers to entry. It is important to work within the system rather than trying to replace it entirely.

Q: How do you see companies in this space being acquired or going public?

There are various possibilities for exits for companies in this space. Traditional technology companies or life science companies could acquire these companies depending on their focus. For example, a pharmaceutical company may acquire a company with a promising therapy, while a technology company may see value in acquiring a company focused on digital therapeutics. The IPO market could also be an option, depending on the company's growth and success.

Q: What return multiples do you expect in this space?

The return multiples in this space are expected to be more in line with software multiples rather than traditional life science multiples. These companies are fundamentally software companies and have the potential for high margins and scalability. By de-risking the investment at every stage and leveraging technology, the return multiples can be comparable to successful software companies.

Q: What has surprised you about being a VC?

One surprising aspect of being a VC is how similar it is to what Vijay has done in the past. The goal of finding and supporting the best people to do grand things remains the same, whether in a startup or in venture capital. The similarities in the process and the people involved have been a pleasant surprise.

Q: Can you tell us about a company that could have a significant impact in the next five to ten years?

Vijay mentions the company PreNOM as an example of a company that could make a significant impact in the next few years. PreNOM is focused on changing the way cancer is approached by shifting the perspective to early detection and prevention. Using machine learning and genomics, they aim to make cancer screenings as routine as going to the dentist, resulting in the potential eradication of cancer. This change in perspective has the potential to transform the healthcare industry.

Takeaways

The intersection of technology and biology presents a unique opportunity to revolutionize healthcare. By leveraging software, machine learning, and mobile platforms, behavioral therapies can be scaled, diseases can be detected earlier, and biology can be programmed. Entrepreneurs in this space are often multidisciplinary, with expertise in both technology and life sciences. Challenges and opportunities exist in working within the regulatory framework of the healthcare industry. Exits for companies in this space can come through acquisition by traditional technology or life science companies or through successful IPOs. Return multiples in this space are expected to resemble software multiples rather than traditional life science multiples. Overall, this new approach has the potential to transform the way healthcare is delivered and drive significant innovation in the field.

Summary & Key Takeaways

• Pandey emphasizes that the combination of software and biotech offers unique opportunities to de-risk investments and achieve great revenue growth.

• Digital therapeutics, computational medicine, and cloud biology are three areas of focus for Andreessen Horowitz in the healthcare sector.

• Digital therapeutics aim to scale existing behavioral therapies for conditions like type 2 diabetes and PTSD, while computational medicine leverages machine learning for early cancer detection. Cloud biology involves making biology resemble programming to advance research.